These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36387909)
1. Graves' disease, its treatments, and the risk of atrial fibrillation: A Korean population-based study. Cho YY; Kim B; Choi D; Kim CH; Shin DW; Kim JS; Park SJ; Kim SW; Chung JH; Han K; Kim TH Front Endocrinol (Lausanne); 2022; 13():1032764. PubMed ID: 36387909 [TBL] [Abstract][Full Text] [Related]
2. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study. Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936 [TBL] [Abstract][Full Text] [Related]
3. Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease. Nishio R; Uchida T; Suzuki L; Onose H; Goto H; Yamada E; Satoh H; Watada H Thyroid; 2021 Mar; 31(3):439-445. PubMed ID: 32729394 [No Abstract] [Full Text] [Related]
4. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism. Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765 [No Abstract] [Full Text] [Related]
5. Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves' disease. Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Liu SYW; Lam CLK; Lang BHH Br J Surg; 2022 Mar; 109(4):381-389. PubMed ID: 35136950 [TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease. Kim MJ; Cho SW; Kim YA; Choi HS; Park YJ; Park DJ; Cho BY Endocrinol Metab (Seoul); 2022 Jun; 37(3):524-532. PubMed ID: 35709827 [TBL] [Abstract][Full Text] [Related]
7. Graves' Disease and the Risk of End-Stage Renal Disease: A Korean Population-Based Study. Cho YY; Kim B; Shin DW; Jang HR; Kim BY; Jung CH; Kim JH; Kim SW; Chung JH; Han K; Kim TH Endocrinol Metab (Seoul); 2022 Apr; 37(2):281-289. PubMed ID: 35381687 [TBL] [Abstract][Full Text] [Related]
8. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440 [TBL] [Abstract][Full Text] [Related]
9. Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study. Song E; Koo MJ; Noh E; Hwang SY; Park MJ; Kim JA; Roh E; Choi KM; Baik SH; Cho GJ; Yoo HJ Endocrinol Metab (Seoul); 2021 Dec; 36(6):1277-1286. PubMed ID: 34915605 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of Graves' Disease Patients Following Antithyroid Drugs, Radioactive Iodine, or Thyroidectomy as the First-line Treatment. Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Lam CLK; Lang BHH Ann Surg; 2021 Jun; 273(6):1197-1206. PubMed ID: 33914484 [TBL] [Abstract][Full Text] [Related]
11. The adjunctive use of carbimazole during radioactive iodine treatment reduces the cure rate of Graves' disease. Docrat F; Mokoena T; Karusseit VOL; Ankrah AO S Afr Med J; 2021 Feb; 111(2):176-179. PubMed ID: 33944730 [TBL] [Abstract][Full Text] [Related]
12. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis. Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology, management and outcomes of Graves' disease-real life data. Hussain YS; Hookham JC; Allahabadia A; Balasubramanian SP Endocrine; 2017 Jun; 56(3):568-578. PubMed ID: 28478488 [TBL] [Abstract][Full Text] [Related]
14. The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea. Park SY; Kim BH; Kim M; Hong AR; Park J; Park H; Choi MS; Kim TH; Kim SW; Kang HC; Chung JH Endocrine; 2021 Oct; 74(1):120-127. PubMed ID: 33860431 [TBL] [Abstract][Full Text] [Related]
15. Circulating microRNA-1a is a biomarker of Graves' disease patients with atrial fibrillation. Wang F; Zhang SJ; Yao X; Tian DM; Zhang KQ; She DM; Guo FF; Zhai QW; Ying H; Xue Y Endocrine; 2017 Jul; 57(1):125-137. PubMed ID: 28547036 [TBL] [Abstract][Full Text] [Related]
16. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience. Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149 [TBL] [Abstract][Full Text] [Related]
17. Graves' disease and the risk of Parkinson's disease: a Korean population-based study. Cho YY; Kim B; Shin DW; Youn J; Mok JO; Kim CH; Kim SW; Chung JH; Han K; Kim TH Brain Commun; 2022; 4(1):fcac014. PubMed ID: 35187486 [TBL] [Abstract][Full Text] [Related]
19. Use of cold iodine in patients with Graves' disease: observations from a clinical practice. Hao ST; Reasner CA; Becker RA Endocr Pract; 2001; 7(6):438-42. PubMed ID: 11747279 [TBL] [Abstract][Full Text] [Related]
20. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea. Seo GH; Cho YY; Chung JH; Kim SW Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]